References
- Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13–21
- Reed SI. The ubiquitin-proteasome pathway in cell cycle control. Results Probl Cell Differ 2006;42:147–81
- Löwe J, Stock D, Jap B, et al. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995;268:533–9
- Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801–47
- Groll M, Ditzel L, Löwe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463–71
- Groll M, Heinemeyer W, Jäger S, et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci USA 1999;96:10976–83
- Heinemeyer W, Fischer M, Krimmer T, et al. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. J Biol Chem 1997;272:25200–9
- Nussbaum AK, Dick TP, Keilholz W, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 1998;95:12504–9
- Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007;107:687–717
- Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739–58
- Nazif T, Bogyo M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Natl Acad Sci USA 2001;98:2967–72
- Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012;19:99–115
- Groll M, Huber R, Moroder L. The persisting challenge of selective and specific proteasome inhibition. J Pept Sci 2009;15:58–66
- Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 2010;10:232–56
- Micale N, Scarbaci K, Troiano V, et al. Peptide-based proteasome inhibitors in anticancer drug design. Med Res Rev 2014;34:1001–69
- Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008;51:1068–72
- Mroczkiewicz M, Winkler K, Nowis D, et al. Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach. J Med Chem 2010;53:1509–18
- Bazzaro M, Anchoori RK, Mudiam MK, et al. α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem 2011;54:449–56
- Desvergne A, Genin E, Maréchal X, et al. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. J Med Chem 2013;56:3367–78
- Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417–21
- Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383–91
- Marastoni M, Baldisserotto A, Canella A, et al. Arecoline tripeptide inhibitors of proteasome. J Med Chem 2004;47:1587–90
- Marastoni M, Baldisserotto A, Trapella C, et al. P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors. Bioorg Med Chem Lett 2006;16:3125–30
- Baldisserotto A, Ferretti V, Destro F, et al. Alpha,beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors. J Med Chem 2010;53:6511–15
- Franceschini C, Trapella C, Calia R, et al. C-terminal trans, trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors. J Enzyme Inhib Med Chem 2013;28:1034–9
- Ahn JH, Cho SY, Ha JD, et al. Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett 2002;12:1941–6
- Urbanek RA, Suchard SJ, Steelman GB, et al. Potent reversible inhibitors of the protein tyrosine phosphatase CD45. J Med Chem 2001;44:1777–93
- Brun MP, Braud E, Angotti D, et al. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity. Bioorg. Med Chem 2005;13:4871–9
- Lawrence HR, Kazi A, Luo Y, et al. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorg Med Chem 2010;18:5576–92
- Xu K, Xiao Z, Tang YB, et al. Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors. Bioorg Med Chem Lett 201;22:2772–4
- Ge Y, Kazi A, Marsilio F, et al. Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. J Med Chem 2012;55:1978–98
- Aubineau T, Cossy J. Chemoselective alkynylation of N-sulfonylamides versus amides and carbamates – synthesis of tetrahydropyrazine. Chem Commun 2013;49:3303–5
- Gavioli R, Vertuani S, Masucci MG. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors. Int J Cancer 2002;101:532–8
- Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989;119:203–10
- Groll M, Kim KB, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α′, β′-epoxyketone proteasome inhibitor. J Am Chem Soc 2000;122:1237–8
- List A, Zeiler E, Gallastegui N, et al. Omuralide and vibralactone: differences in the proteasome-β-lactone-γ-lactam binding scaffold alter target preferences. Angew Chem Int Ed Engl 2014;53:571–4
- Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996;17:490–519